Skip to main content
    A

    ARS Pharmaceuticals, Inc (SPRY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.59
    -0.30 (-7.71%)

    Market Cap: $391.06M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ARS Pharmaceuticals, Inc (SPRY) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect ARS Pharmaceuticals (SPRY) to earn -$1.87 per share in the fiscal year ending Dec 31, 2026, on revenue of $121.42M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy4100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 40.1%.

    Fiscal year ending Dec 31, 2026
    -$1.87
    EPS consensus, revenue $121.42M
    Fiscal year ending Dec 31, 2027
    -$0.86
    EPS consensus, revenue $170.09M
    Next report
    Mar 8, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.87-$1.89 to -$1.852$121.42M$116.33M to $125.10M4
    Dec 31, 2027-$0.86-$0.97 to -$0.713$170.09M$142.06M to $202.21M4

    Quarterly Estimates

    The EPS consensus falls from -$0.31 for the quarter ending Dec 31, 2026 to -$0.34 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.31-$0.41 to -$0.176$28.65M$24.01M to $32.66M6
    Mar 31, 2027-$0.34-$0.41 to -$0.272$24.54M$24.50M to $24.58M2

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 4 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202612
    Fiscal year ending Dec 31, 202721
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.72.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.87-$1.88-$1.87-$1.84-$1.72N/A
    Fiscal year ending Dec 31, 2027-$0.86-$0.90-$0.90-$0.89-$0.94N/A
    Quarter ending Mar 31, 2027-$0.34-$0.39-$0.39-$0.39-$0.25N/A

    Frequently Asked Questions About SPRY

    What is the SPRY stock forecast?

    Consensus analyst estimates put ARS Pharmaceuticals's EPS at -$1.87 for the fiscal year ending Dec 31, 2026, on revenue of $121.42M. The consensus rating from 4 analysts is Buy.

    How do analysts rate SPRY stock?

    Of 4 analysts covering ARS Pharmaceuticals, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from SPRY next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.87, with estimates from -$1.89 to -$1.85 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.86, with estimates from -$0.97 to -$0.71 from 3 analysts.

    What revenue do analysts expect from ARS Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $121.42M, with estimates from $116.33M to $125.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $170.09M, with estimates from $142.06M to $202.21M.

    How many analysts cover SPRY?

    4 analysts rate ARS Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.